Zdrowie i gospodarka · 18/04/2013
FDA Withdraws OXYCONTIN Extended-Release Tablets from Sale Due to Safety or Effectiveness Concerns
The FDA has withdrawn OXYCONTIN extended-release tablets from sale due to safety or effectiveness concerns, and will not accept new applications referencing NDA 20-553. The agency made this determination for the 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg, and 160mg formulations approved under NDA 20-553.